1. What drives quality of life in multiple sclerosis?;Hemmett L;QJM,2004
2. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances;Egeberg MD;Clin Ther,2012
3. FDA Drug Safety Communication. seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine). (2016). Accessed: April 13, 2020: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-seizure-risk-multiple-sclerosis-....
4. FDA adverse event reporting system (FAERS) public dashboard. (2020). Accessed. August 5, 2020: https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/a....
5. Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis;Jeffery DR;Core Evid,2010